HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes : A randomized controlled trial

Creative Commons License

Files in This Item:
Takase_et_al-2019-Journal_of_Diabetes_Investigation.pdf311.33 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/74767

Title: Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes : A randomized controlled trial
Authors: Takase, Takahiro Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Yamamoto, Chiho Browse this author
Nomoto, Hiroshi Browse this author
Miya, Aika Browse this author
Dannoura, Midori Browse this author
Cho, Kyu Yong Browse this author
Kurihara, Yoshio Browse this author
Manda, Naoki Browse this author
Aoki, Shin Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: Dulaglutide
Treatment satisfaction
Type 2 diabetes
Issue Date: May-2019
Publisher: Wiley
Journal Title: Journal of Diabetes Investigation
Volume: 10
Start Page: 699
End Page: 705
Publisher DOI: 10.1111/jdi.12906
PMID: 30076787
Abstract: Aims/Introduction: We compared treatment satisfaction in type 2 diabetes patients taking daily and weekly glucagon-like peptide-1 receptor agonists. Materials and Methods: The study was a 12-week, multicenter, open-label, prospective, randomized, parallel-group comparison trial. The participants were Japanese patients with type 2 diabetes being administered with the glucagon-like peptide-1 receptor agonist, liraglutide, daily for >3 months. Patients were randomly assigned to either continue taking liraglutide once daily (Lira group) or switch to dulaglutide once weekly (Dula group). The primary outcome was the change in the Diabetes Treatment Satisfaction Questionnaire score from baseline to week 12 in the two groups. The secondary outcomes comprised changes in the Diabetes Therapy-Related Quality of Life score, body mass and glycemic control. Results: A total of 33 participants were initially enrolled in the trial, and 31 participants completed the protocol. The change in the Diabetes Treatment Satisfaction Questionnaire score in the Dula group was significantly greater than that in the Lira group (+0.1 – 4.7 in the Lira group vs +4.9 – 5.2 in the Dula group; P = 0.013). The change in Diabetes Therapy- Related Quality of Life score in the Dula group was significantly greater than that in the Lira group (-3.7 – 6.9 vs +8.9 – 15.1; P = 0.007). There were no significant differences between groups in the changes in body mass, plasma glucose or glycated hemoglobin. Conclusions: Weekly administration of dulaglutide was superior to liraglutide with regard to treatment satisfaction in patients with type 2 diabetes, in the absence of any negative effect on glycemic control.
Rights: https://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/74767
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University